Clinical Trials Logo

Ibrutinib Resistance clinical trials

View clinical trials related to Ibrutinib Resistance.

Filter by:
  • None
  • Page 1

NCT ID: NCT03513562 Active, not recruiting - Clinical trials for Chronic Lymphocytic Leukemia

Venetoclax and Ibrutinib in Treating in Participants With Chronic Lymphocytic Leukemia and Ibrutinib Resistance Mutations

Start date: March 26, 2019
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well venetoclax and ibrutinib work in treating participants with chronic lymphocytic leukemia and have developed genetic mutations after previously being treated with ibrutinib. Venetoclax and ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.